vs
汉瑞祥（HSIC）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
Raymond James Financial的季度营收约是汉瑞祥的1.1倍（$3.9B vs $3.4B），Raymond James Financial净利率更高（14.1% vs 2.9%，领先11.2%），Raymond James Financial同比增速更快（13.0% vs 7.7%），过去两年汉瑞祥的营收复合增速更高（4.1% vs 1.3%）
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
HSIC vs RJF — 直观对比
营收规模更大
RJF
是对方的1.1倍
$3.4B
营收增速更快
RJF
高出5.3%
7.7%
净利率更高
RJF
高出11.2%
2.9%
两年增速更快
HSIC
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $3.4B | $3.9B |
| 净利润 | $101.0M | $544.0M |
| 毛利率 | 30.9% | — |
| 营业利润率 | 4.7% | — |
| 净利率 | 2.9% | 14.1% |
| 营收同比 | 7.7% | 13.0% |
| 净利润同比 | 7.4% | 10.0% |
| 每股收益（稀释后） | $0.85 | $2.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HSICRJF
| Q1 26 | — | $3.9B | ||
| Q4 25 | $3.4B | $4.2B | ||
| Q3 25 | $3.3B | $4.2B | ||
| Q2 25 | $3.2B | $3.8B | ||
| Q1 25 | $3.2B | $3.8B | ||
| Q4 24 | $3.2B | $4.0B | ||
| Q3 24 | $3.2B | $4.0B | ||
| Q2 24 | $3.1B | $3.8B |
净利润HSICRJF
| Q1 26 | — | $544.0M | ||
| Q4 25 | $101.0M | $563.0M | ||
| Q3 25 | $101.0M | $604.0M | ||
| Q2 25 | $86.0M | $436.0M | ||
| Q1 25 | $110.0M | $495.0M | ||
| Q4 24 | $94.0M | $600.0M | ||
| Q3 24 | $99.0M | $602.0M | ||
| Q2 24 | $104.0M | $492.0M |
毛利率HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | 30.9% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 31.4% | — | ||
| Q1 25 | 31.6% | — | ||
| Q4 24 | 31.1% | — | ||
| Q3 24 | 31.3% | — | ||
| Q2 24 | 32.5% | — |
营业利润率HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 4.7% | 14.7% | ||
| Q1 25 | 5.5% | 17.5% | ||
| Q4 24 | 4.9% | 18.6% | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 5.1% | 17.1% |
净利率HSICRJF
| Q1 26 | — | 14.1% | ||
| Q4 25 | 2.9% | 13.5% | ||
| Q3 25 | 3.0% | 14.4% | ||
| Q2 25 | 2.7% | 11.3% | ||
| Q1 25 | 3.5% | 12.9% | ||
| Q4 24 | 2.9% | 14.9% | ||
| Q3 24 | 3.1% | 15.0% | ||
| Q2 24 | 3.3% | 13.1% |
每股收益（稀释后）HSICRJF
| Q1 26 | — | $2.83 | ||
| Q4 25 | $0.85 | $2.79 | ||
| Q3 25 | $0.84 | $2.96 | ||
| Q2 25 | $0.70 | $2.12 | ||
| Q1 25 | $0.88 | $2.36 | ||
| Q4 24 | $0.75 | $2.86 | ||
| Q3 24 | $0.78 | $2.85 | ||
| Q2 24 | $0.80 | $2.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $156.0M | $5.4B |
| 总债务越低越好 | $2.3B | — |
| 股东权益账面价值 | $3.2B | $52.0M |
| 总资产 | $11.2B | $91.9B |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资HSICRJF
| Q1 26 | — | $5.4B | ||
| Q4 25 | $156.0M | $9.9B | ||
| Q3 25 | $136.0M | $11.4B | ||
| Q2 25 | $145.0M | $9.2B | ||
| Q1 25 | $127.0M | $9.7B | ||
| Q4 24 | $122.0M | $10.0B | ||
| Q3 24 | $126.0M | $11.0B | ||
| Q2 24 | $138.0M | $9.1B |
总债务HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — |
股东权益HSICRJF
| Q1 26 | — | $52.0M | ||
| Q4 25 | $3.2B | $12.6B | ||
| Q3 25 | $3.4B | $12.5B | ||
| Q2 25 | $3.4B | $12.3B | ||
| Q1 25 | $3.3B | $12.2B | ||
| Q4 24 | $3.4B | $11.9B | ||
| Q3 24 | $3.5B | $11.7B | ||
| Q2 24 | $3.5B | $11.2B |
总资产HSICRJF
| Q1 26 | — | $91.9B | ||
| Q4 25 | $11.2B | $88.8B | ||
| Q3 25 | $11.1B | $88.2B | ||
| Q2 25 | $10.9B | $84.8B | ||
| Q1 25 | $10.5B | $83.1B | ||
| Q4 24 | $10.2B | $82.3B | ||
| Q3 24 | $10.6B | $83.0B | ||
| Q2 24 | $10.3B | $80.6B |
负债/权益比HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.59× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $381.0M | — |
| 自由现金流经营现金流 - 资本支出 | $338.0M | — |
| 自由现金流率自由现金流/营收 | 9.8% | — |
| 资本支出强度资本支出/营收 | 1.3% | — |
| 现金转化率经营现金流/净利润 | 3.77× | — |
| 过去12个月自由现金流最近4个季度 | $573.0M | — |
8季度趋势，按日历期对齐
经营现金流HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | $381.0M | $-10.0M | ||
| Q3 25 | $174.0M | $796.0M | ||
| Q2 25 | $120.0M | $691.0M | ||
| Q1 25 | $37.0M | $117.0M | ||
| Q4 24 | $204.0M | $830.0M | ||
| Q3 24 | $151.0M | $510.0M | ||
| Q2 24 | $296.0M | $711.0M |
自由现金流HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | $338.0M | $-56.0M | ||
| Q3 25 | $141.0M | $752.0M | ||
| Q2 25 | $88.0M | $634.0M | ||
| Q1 25 | $6.0M | $71.0M | ||
| Q4 24 | $168.0M | $789.0M | ||
| Q3 24 | $117.0M | $460.0M | ||
| Q2 24 | $259.0M | $655.0M |
自由现金流率HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | 9.8% | -1.3% | ||
| Q3 25 | 4.2% | 17.9% | ||
| Q2 25 | 2.7% | 16.5% | ||
| Q1 25 | 0.2% | 1.8% | ||
| Q4 24 | 5.3% | 19.6% | ||
| Q3 24 | 3.7% | 11.5% | ||
| Q2 24 | 8.3% | 17.4% |
资本支出强度HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 1.1% | ||
| Q3 25 | 1.0% | 1.1% | ||
| Q2 25 | 1.0% | 1.5% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | 1.1% | 1.0% | ||
| Q3 24 | 1.1% | 1.2% | ||
| Q2 24 | 1.2% | 1.5% |
现金转化率HSICRJF
| Q1 26 | — | — | ||
| Q4 25 | 3.77× | -0.02× | ||
| Q3 25 | 1.72× | 1.32× | ||
| Q2 25 | 1.40× | 1.58× | ||
| Q1 25 | 0.34× | 0.24× | ||
| Q4 24 | 2.17× | 1.38× | ||
| Q3 24 | 1.53× | 0.85× | ||
| Q2 24 | 2.85× | 1.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
RJF
| Private Client Group | $2.8B | 73% |
| Bank | $486.0M | 13% |
| Capital Markets | $464.0M | 12% |
| Other | $99.0M | 3% |
